Navigation Links
Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
Date:3/18/2013

SEATTLE, March 18, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced financial results for the fourth quarter and year ended December 31, 2012.

Financial ResultsTotal operating expenses for the three months ended December 31, 2012 were $9.1 million, compared to $11.0 million for the same period in 2011.  Omeros received a $3.95 million payment from its insurer during the 2012 period as reimbursement for an expense recognized by Omeros in the third quarter of 2012. Excluding this reimbursement, Omeros' operating expenses increased during the 2012 period related to advancing its MASP-2 program toward the clinic, marketing expenses in connection with the planned 2014 commercial launch of OMS302, and increased legal costs and employee compensation, including non-cash stock-based compensation. These increases were partially offset by lower expenses related to Omeros' OMS302 and OMS103HP Phase 3 clinical programs and its PDE10, PDE7 and Plasmin programs. 

Total operating expenses for the year ended December 31, 2012 were $42.9 million, compared to $31.9 million in 2011. The increase was primarily due to higher expenses related to Omeros' OMS302 Phase 3 clinical program and marketing costs tied to the drug's planned 2014 commercial launch, advancing its PDE10 and MASP-2 programs into and toward the clinic, respectively, the Company's GPCR program, and increased legal costs and employee compensation, including non-cash stock-based compensation. These increases were partially offset by lower expenses in Omeros' OMS103HP program and in several of its preclinical programs, including its PDE7 and Plasmin programs.For the quarte
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
2. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
3. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
4. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
5. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
6. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
7. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2013
8. Testing Positive for Stability & Growth - Research Report on CombiMatrix Corporation, Cepheid, PerkinElmer, Inc., Life Technologies Corp. and Laboratory Corp. of America Holdings
9. R&D, Innovation Key to Success - Research Report on Varian Medical Systems, Inc., Boston Scientific Corporation, Stryker Corporation, St. Jude Medical, Inc., and Thermo Fischer Scientific Inc.
10. FibeRio® Technology Corporation Announces Strategic Investment Financing Led by SABIC and Aster Capital
11. Celsion Corporation Announces $15 Million Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... have succeeded in measuring vibrational motion of a single ... how vibration of a single molecule differs from the ... was performed at the University of California, Irvine, where ... works as a visiting fellow under professor Vartkess A. ... team was lead by Professor Eric O. Potma. The ...
(Date:8/20/2014)... Francisco, CA (PRWEB) August 20, 2014 ... Conference is being held on October 29-30 in ... perspectives from industry, academic and government researchers and clinicians ... in the space. , In the twelve years ... one hundred therapies have been introduced with pharmacogenetic information ...
(Date:8/20/2014)... GraphDB™ 6.0 from ... to the enterprise replication cluster, faster loading speeds, ... and Elasticsearch. This release happens to coincide with ... – GraphDB™ was formerly known as OWLIM. ... mature enterprise resilient RDF triplestore will also benefit ...
(Date:8/19/2014)... 19, 2014 Cellgen Diagnostics ... $200,000 to fund a corporate lab for its ... This development is a critical component in the ... to the implementation of personalized medicine – a ... medicine. , Indiegogo contributions will support Cellgen’s intent ...
Breaking Biology Technology:Seeing a molecule breathe 26th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3
... Calif., Oct. 5 Bionovo, Inc.,(Nasdaq: BNVI ), a ... in the areas of women,s health and cancer, today announced,that ... at the 4th,Annual BIO Investor Forum. The presentation will ... the Palace Hotel in San Francisco, CA. A live ...
... Cerimon,Pharmaceuticals, Inc., today announced Paul Sekhri, Cerimon,s ... 2007 BIO Investor Forum on,Thursday, October 11, 2007, ... in San,Francisco. The presentation will take place in ... Cerimon Pharmaceuticals, Inc. is a biopharmaceutical company ...
... Coalition for a,Competitive Pharmaceutical Market (CCPM) issued the ... announcement regarding its,"Generic Initiative for Value and Efficiency" ... grappling with,how to manage escalating prescription drug costs, ... focus on ways to enhance timely generic access.,Today,s ...
Cached Biology Technology:CCPM Issues Statement on FDA's GIVE Initiative 2
(Date:8/19/2014)... Aug. 19, 2014 To improve students, chances ... grades, the University of Houston (UH) implemented a ... students at risk for failure. , Through ... Board (THECB), the Department of Biology and Biochemistry ... students taking "General Biology" for non-majors and "Introductory ...
(Date:8/19/2014)... of the world, leprosy and tuberculosis live side-by-side. ... leprosy per year, with nearly all of them ... century-old vaccine Bacille Calmette-Guerin, or BCG, provides only ... a more potent vaccine is needed to combat ... stronger weapon against both diseases., In a study ...
(Date:8/19/2014)... Aug. 19, 2014 ) -- Scientists at the Houston ... up and transfer single cells using a pipette -- ... describe this engineering feat and preliminary test results in ... American Chemical Society . , "Studying single cells and ... biomedical research," said nanomedicine department. faculty member Lidong Qin, ...
Breaking Biology News(10 mins):University of Houson program earns kudos for improving grades, retaining students 2University of Houson program earns kudos for improving grades, retaining students 3New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2Moving single cells around -- accurately and cheaply 2
... century, scientists have struggled with plutonium contamination spreading further ... in humans and animals. It was known nanometer ... no one had been able to study its structure ... groundwater. Scientists at the U.S. Department of ...
... Spanish flu outbreak of 1918 killed between 30 and ... cause of death was acute respiratory distress syndrome (ARDS). ... body during which the lung becomes severely damaged. ARDS ... but also by chemical agents. These could be toxic ...
... the most common cause of episodic headache, and by ... visit. It affects some 15% of the population, including ... considerable burden on healthcare in both the developed and ... years, great strides have been made in discovering common ...
Cached Biology News:Scientists discover how nanocluster contaminants increase risk of spreading 2New strategies against bird flu 2Concentrating on different aspects of pain leads to breakthrough in migraine genetics 2
High affinity antibody reacting with S-100 ab heterodimer. Could be used for Western blotting application and immunoassay....
... (g/L):,Tryptone, 10 ,Yeast extract, 5 ,Sodium ... ,Ferric ammonium citrate, 0.5 ,IPTG, 0.03 ... soluble, autoclavable chromogenic substrate for -galactosidase. ... -galactosidase generates a black insoluble precipitate. ...
S-100 alpha/beta chain (8B10)...
SCCRO (S-17)...
Biology Products: